Biogen Idec, Inc. (Massachusetts) Still Gauging Impact of Rival Novartis AG MS Drug

Reuters -- Biogen Idec (BIIB.O) expects a new rival drug from Novartis AG (NOVN.VX) to affect its flagship multiple sclerosis franchise, but the company's chief executive officer believes it is too early to gauge the extent of any sales erosion.